アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m) - antifungal - proven clinically effective in the treatment of most athlete's foot, jock itch, and ringworm - for effective relief of itching, scaling, cracking, burning, and discomfort

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - anti-itch - temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to eczema psoriasis insect bites poison ivy, oak, sumac detergents jewelry cosmetics soaps seborrheic dermatitis - eczema - psoriasis - insect bites - poison ivy, oak, sumac - detergents - jewelry - cosmetics - soaps - seborrheic dermatitis - temporarily relieves external anal and genital itching - other uses of this product should be only under the advice and supervision of a doctor

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - anti-itch - temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to eczema psoriasis insect bites poison ivy, oak, sumac detergents jewelry cosmetics soaps seborrheic dermatitis - eczema - psoriasis - insect bites - poison ivy, oak, sumac - detergents - jewelry - cosmetics - soaps - seborrheic dermatitis - temporarily relieves external anal and genital itching - other uses of this product should be only under the advice and supervision of a doctor

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - anti-itch - temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to eczema psoriasis insect bites poison ivy, oak, sumac detergents jewelry cosmetics soaps seborrheic dermatitis - eczema - psoriasis - insect bites - poison ivy, oak, sumac - detergents - jewelry - cosmetics - soaps - seborrheic dermatitis - temporarily relieves external anal and genital itching - other uses of this product should be only under the advice and supervision of a doctor

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - docosanol (unii: 9g1oe216xy) (docosanol - unii:9g1oe216xy) - cold sore/fever blister treatment - treats cold sores/fever blisters on the face or lips - shortens healing time and duration of symptoms: - tingling, pain, burning, and/or itching

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - minoxidil (unii: 5965120sh1) (minoxidil - unii:5965120sh1) - hair regrowth treatment for men to regrow hair on the top of the scalp (vertex only, see pictures on side of carton)

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v) - antihistamine temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: - runny nose - itchy, watery eyes - sneezing - itching of the nose or throat

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) -

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr) -

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

h2-pharma, llc - etoposide phosphate (unii: 528xyj8l1n) (etoposide - unii:6plq3cp4p3) - etopophos is indicated, in combination with other chemotherapeutic drugs, for treatment of patients with refractory testicular tumors. etopophos is indicated, in combination with cisplatin, for first-line treatment of patients with small cell lung cancer. etopophos is contraindicated in patients with a history of a severe hypersensitivity reaction to etoposide products [see warnings and precautions (5.3)] . risk summary based on animal data and its mechanism of action, etopophos can cause fetal harm when administered to a pregnant woman. etoposide, the active moiety of etoposide phosphate is teratogenic in mice and rats (see data) . advise pregnant women of the potential hazard to a fetus. advise women of childbearing potential to avoid becoming pregnant. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in rats, an intravenous etoposide dose of 0.4 mg/kg/day (about 0.05 times of the 50 mg/m2 human dose based on body surface area [bsa]) during organogenesis caused maternal toxicity, embryotoxicity, and teratogenicity (skeletal abnormalities, exencephaly, encephalocele, and anophthalmia); higher doses of 1.2 and 3.6 mg/kg/day (about 0.14 and 0.5 times the 50 mg/m2 human dose based on bsa) resulted in 90% and 100% embryonic resorptions. in mice, a single etoposide dose of 1.0 mg/kg (approximately 0.06 times the 50 mg/m2 human dose based on bsa) administered intraperitoneally on days 6, 7, or 8 of gestation caused embryotoxicity, cranial abnormalities, and major skeletal malformations. an intraperitoneal dose of 1.5 mg/kg (about 0.1 times the 50 mg/m2 human based on bsa) on day 7 of gestation caused an increase in the incidence of intrauterine death and fetal malformations and a significant decrease in the average fetal body weight [see nonclinical toxicology (13.1)] . there is no information regarding the presence of etoposide in human milk or its effects on breastfed infant milk production. because of the potential for serious adverse reactions in nursing infants from etopophos, advise women not to breastfeed during treatment with etopophos. contraception females advise females of reproductive potential to use effective contraception during treatment with etopophos and for 6 months after the final dose. males etopophos may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. males with female sexual partners of reproductive potential should use effective contraception during treatment with etopophos and for 4 months after the final dose. infertility females in females of reproductive potential, etopophos may cause infertility and result in amenorrhea. premature menopause can occur with etopophos. recovery of menses and ovulation is related to age at treatment. males in male patients, etopophos may result in oligospermia, azoospermia, and permanent loss of fertility. sperm counts have been reported to return to normal levels in some men, and in some cases, have occurred several years after the end of therapy [see nonclinical toxicology (13.1)] . safety and effectiveness in pediatric patients have not been established. clinical studies of etoposide did not include sufficient numbers (n=71) of patients aged 65 years and over to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between elderly and younger patients.